Biosystems International | GenomeWeb

Biosystems International

The figure comes from a report commissioned by proteomics firm Proteome Sciences, which, like a number of other protein biomarker firms including Quanterix, Rules-Based Medicine, and NextGen Sciences, has made AD a significant focus of its R&D and commercialization efforts.

Funded by the French innovation agency OSEO, the collaboration calls for the companies to develop a prototype blood-based protein biomarker test for Alzheimer's disease as well as a therapeutic for the disease and a companion diagnostic.

The merger will give Biosystems International access to MicroBioChips' nanoarray technology and its sales and marketing resources, which are expected to help the company establish new relationships with university-based proteomics laboratories and pharma and biotech firms.

The Paris-based firms earlier this year announced a partnership to develop monoclonal antibody microarrays that combine BSI's antibodies with MBC's microarray platform.

The firms will combine Biosystems International's monoclonal antibody proteomics process with MBC's microarray technology.

The company will be using the funds to develop and test a prototype of the diagnostic, which it hopes to bring to market sometime in 2011, said a company official.

The Paris-based protein biomarker firm will use the money to further develop and commercialize its early-stage lung cancer diagnostics test.

A Karmagenes researcher has lost his position after reportedly admitting to data fabrication, according to Retraction Watch.

Two neuroscientists write in Nature News that solving the "reproducibility crisis" in science may require changing the requirements for publication.

In Nature this week: genomic analysis of prehistoric New Mexicans, a nanopore method for mapping DNA methylation, and more.

A new study finds that adding missing good bacteria to the skin microbiome of atopic dermatitis patients decreases Staphylococcus aureus colonization.